Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04963283 |
|
Recruitment Status :
Recruiting
First Posted : July 15, 2021
Last Update Posted : December 15, 2022
|
Sponsor:
University of Colorado, Denver
Collaborators:
National Cancer Institute (NCI)
Criterium, Inc.
Bristol-Myers Squibb
Exelixis
Information provided by (Responsible Party):
University of Colorado, Denver
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 9, 2024 |
| Estimated Study Completion Date : | February 9, 2025 |